From October 23 to 27 (local time), the 2026 European Society for Medical Oncology (ESMO) Congress was held in Madrid, Spain. Studies on 2 investigational products and 3 marketed products from Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), were selected for presentation.

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), released the results of a Phase II clinical study evaluating TQB2102 in combination with benmelstobart (TQB2450) ± capecitabine as first-line treatment for HER2-positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC).

On October 23 (local time), at the 2026 European Society for Medical Oncology (ESMO) Congress held in Madrid, Spain, TQB2102, a new-generation HER2 bispecific antibody-drug conjugate (ADC) independently developed by Chia Tai Tianqing, a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 1177.HK), announced the latest data from the pivotal Phase III clinical study (APEX-Breast01) for the treatment of HER2-low advanced breast cancer.

Recently, CTTQ (Chia Tai Tianqing), a core enterprise of Sino Biopharmaceutical Limited (SBP Group, 01177.HK), signed an agreement with the National Natural Science Foundation of China (NSFC) to contribute 100 million RMB to participate in the Joint Fund for Innovation and Development of Private Enterprises of the National Natural Science Foundation (hereinafter referred to as the "Joint Fund").